Exoduspoint Capital Management Adds $14M in Cogent Biosciences, Inc. ($COGT)

Exoduspoint Capital Management has opened a new position in Cogent Biosciences, Inc. (NasdaqGS: COGT), purchasing 372,175 shares. This new stake is valued at approximately $13.3 million, according to the latest Form 13F filing with the SEC, reflecting holdings as of the end of the reporting period.

What Changed in Exoduspoint Capital Management's Cogent Biosciences Position

Exoduspoint Capital Management initiated a new position in Cogent Biosciences by acquiring 372,175 shares. The total value of this investment stands at about $13.3 million. As this is a brand-new position, there is no previous share count or percentage change to report.

Other Institutional Activity in Cogent Biosciences

In other institutional moves, FMR LLC slightly increased its holdings by 35,781 shares, bringing its total to 23,122,748 shares worth around $890 million. BlackRock, Inc. significantly boosted its position by 3,070,423 shares, ending with 16,045,014 shares valued at about $618 million, marking a 23.7% increase. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both opened new positions, acquiring 7,333,333 shares and 6,894,959 shares respectively, worth approximately $282 million and $265 million. Meanwhile, Janus Henderson Group PLC increased its stake by 1,427,717 shares, a 31.5% rise, resulting in a total of 5,965,125 shares valued at $230 million.

Cogent Biosciences, Inc. Stock Up 11.6%

Shares of Cogent Biosciences, Inc. (NasdaqGS: COGT) traded near $35.84 on Tuesday. The company has a market capitalization of $6.12 billion. Though not currently profitable, it has a forward P/E ratio of -37.5. The stock's beta is 0.35, indicating lower volatility compared to the market. Over the past year, the stock has ranged from a low of $6.92 to a high of $43.73. It has a 50-day moving average of $34.55 and a 200-day moving average of $31.09. The company's current ratio is 15.14, with a quick ratio of 14.94 and a debt-to-equity ratio of 39.27.

Recent Earnings

While specific earnings figures are not detailed, Cogent Biosciences is expected to report its next earnings on August 4, 2026. The company is not currently profitable, with a negative return on equity and net margin.

Insider Buying and Selling at Cogent Biosciences, Inc.

On June 9, 2026, several insiders, including Peter Evan Harwin, Todd Shegog, and Karen Jean Ferrante, each acquired 17,901 shares of Cogent Biosciences. These purchases were not part of a pre-planned trading program.

Analysts Set New Price Targets

Analyst activity has been robust, with HC Wainwright & Co. maintaining a buy rating with a $55 price target as of May 6, 2026. Jefferies assumed coverage with a buy rating and a $55 target on March 16, 2026. Piper Sandler also maintained a buy rating with a $52 target on February 18, 2026. The consensus among 12 analysts is a strong buy, with a mean target price of $54.25.

About Cogent Biosciences

Cogent Biosciences, Inc. is a biotechnology company based in Waltham, Massachusetts. It focuses on developing precision therapies for genetically defined diseases. The company's lead product candidate, bezuclastinib, is in a Phase 3 trial targeting mutations in the KIT receptor tyrosine kinase. Other products in its pipeline include CGT4859, CGT4255, and CGT6297, each targeting specific genetic mutations associated with various cancers.

Bottom Line

Exoduspoint Capital Management's new position in Cogent Biosciences underscores the fund's interest in the biotechnology sector. Investors often track such filings to gauge institutional confidence, though it's important to remember that 13F filings are backward-looking and may not reflect current positions. As Cogent Biosciences continues its clinical trials, the company's developments will be closely watched by investors and analysts alike.